We follow highest level of corporate governance, which is in line with a global company like ours.

Sun Pharma's relationship with AML is on an arm's-length basis. As investors have expressed concerns regarding this arrangement, we are in the process of evaluating various options for undertaking domestic formulation business.

India is a large market where our focus will be to grow faster than the market and add few percentage points to our market share every year.

Generally, we have competed with ourselves... because I feel that if I compete against somebody, it causes stress. I don't want the process of growth to be stressful.

Sun is seeking some products that we don't have or technologies that we don't have.

Our focus is to see that we are growing faster than the industry and, whichever product we launch, we do better than competition. We try and manage our operations better than competition. Essentially, we try to be better than what we were the previous year.

The reason we don't give a date by which we will acquire something is because we don't want to create pressure on ourselves to buy something.

The Ranbaxy acquisition doesn't preclude us from making more large acquisitions. The important issue is whether we have the management bandwidth to handle the acquisition.

I think FDA's concerns are patient-safety.

Analysts estimate that emerging markets are expected to drive 90 percent of the world's pharmaceutical market growth, and differentiated products will be important to this growth.